Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711037 | 1.00 | KDM6B (0.61) | KDM6BPPARGPPARADPP4PIN1 | |
| SCHEMBL5813461 | 0.85 | LDHA (0.51) | KDM6BPPARGPPARADPP4PIN1 | |
| SCHEMBL20586356 | 0.84 | KDM6B (0.56) | KDM6BPPARGPPARAPTPRA | |
| SCHEMBL29551982 | 0.84 | KDM6B (0.56) | KDM6BPPARGPPARAPTPRA | |
| SCHEMBL18248036 | 0.84 | KDM6B (0.56) | KDM6BPPARGPPARAPTPRA | |
| SCHEMBL7706678 | 0.84 | KDM6B (0.46) | KDM6BDPP4PIN1DPP7MAOA | |
| SCHEMBL7707907 | 0.84 | KDM6B (0.46) | KDM6BDPP4PIN1DPP7MAOA | |
| SCHEMBL370923 | 0.84 | DPP4 (0.45) | KDM6BDPP4PIN1DPP7MAOA | |
| SCHEMBL44052 | 0.80 | SLC7A5 (0.62) | — | |
| SCHEMBL6005325 | 0.80 | TBXAS1 (0.44) | PPARADPP4PIN1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6514997-B2 | Block the activity of picornaviral 3C protease | AGOURON PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | KDM6B 2760/4885PPARG 2566/4885PPARA 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.